Autofits

Autofits logo
Menu

21 CFR Part 211: cGMP for Finished Pharmaceuticals and Packaging

21 CFR Part 211: cGMP for Finished Pharmaceuticals and Packaging

21 CFR Part 211 is the U.S. Food and Drug Administration regulation that sets the current good manufacturing practice (cGMP) requirements for finished pharmaceuticals, covering everything from facilities and equipment to production, packaging, labeling, and records. It is the binding federal regulation that drug manufacturers in the United States must follow to ensure their products meet quality, purity, and identity requirements. For packaging, Part 211 includes a dedicated subpart on packaging and labeling controls, and it requires that drug containers and closures do not interact with the product to alter its safety or quality.

This guide explains what 21 CFR Part 211 is, its main subparts, what it requires of packaging and container-closure components, and how it relates to standards like ISO 15378 and the USP chapters.

Key takeaways

  • 21 CFR Part 211 is the FDA’s cGMP regulation for finished pharmaceuticals, binding on drug manufacturers in the United States.
  • It is published in Title 21 of the Code of Federal Regulations and enforced by the FDA.
  • It covers the whole operation: organisation, facilities, equipment, components and containers, production, packaging and labeling controls, holding and distribution, records, and returned products.
  • For packaging, it requires that containers and closures not be reactive, additive, or absorptive to an extent that affects the drug, and it mandates controls over the packaging operation.
  • Part 211 is a regulation (mandatory law); standards like ISO 15378 and the USP chapters are how manufacturers and suppliers demonstrate the underlying quality.
  • A packaging supplier supports its customers’ Part 211 compliance through its own quality system and documentation.

What is 21 CFR Part 211?

21 CFR Part 211 is the section of the U.S. Code of Federal Regulations that establishes the current good manufacturing practice requirements for the manufacture, processing, packing, and holding of finished pharmaceutical products. It is issued and enforced by the U.S. Food and Drug Administration (FDA).

“cGMP” stands for current good manufacturing practice: the “current” signals that expectations evolve with industry practice and technology, so meeting the regulation means meeting today’s accepted standards, not a fixed checklist. Part 211 applies to finished drug products (Part 210 sets out the broader cGMP scope). A product made out of compliance with cGMP is considered adulterated under U.S. law, which is why Part 211 is foundational for any company making finished pharmaceuticals for the U.S. market.

The main subparts of Part 211

Part 211 is organised into subparts that each govern an area of the manufacturing operation. The key subparts include:

Subpart Area
B Organisation and personnel
C Buildings and facilities
D Equipment
E Control of components and drug product containers and closures
F Production and process controls
G Packaging and labeling control
H Holding and distribution
I Laboratory controls
J Records and reports
K Returned and salvaged drug products

Two subparts are especially relevant to packaging: Subpart E, which governs the control of components and of drug product containers and closures (receipt, testing, approval, and storage), and Subpart G, which governs the packaging and labeling operation itself.

What Part 211 requires of packaging and containers

Part 211 requires that drug product containers and closures be suitable for their purpose and not interact with the product in a way that affects its safety, identity, strength, quality, or purity. The regulation expects containers and closures to be controlled like any other component: examined, tested against specifications, approved or rejected, and stored and handled to prevent mix-ups and contamination.

A central principle is that containers and closures must not be reactive, additive, or absorptive to an extent that alters the drug beyond official or established requirements. In other words, the package must protect the product and not change it. The packaging and labeling controls of Subpart G then govern the operation: ensuring the right product gets the right container, closure, and label, with checks to prevent mix-ups, and with tamper-evident features where required for certain products. These requirements are why drug makers qualify their container closure systems carefully and why they expect documentation and consistent quality from their packaging suppliers.

How Part 211 relates to ISO 15378 and the USP chapters

Part 211 is a binding regulation; ISO 15378 and the USP chapters are the standards through which the underlying packaging quality is demonstrated. They operate at different levels but point in the same direction.

  • ISO 15378 applies GMP principles to manufacturers of primary packaging materials, so a packaging supplier’s quality system supports its pharmaceutical customers’ cGMP obligations.
  • USP <660> (glass), the USP <661> series (plastics), and USP <381> and USP <382> (elastomeric closures) provide the test methods and requirements that show containers and closures are suitable, supporting the “not reactive, additive, or absorptive” expectation of Part 211.
  • USP <1207> provides the framework for demonstrating container closure integrity, part of assuring sterility for sterile products.

A drug manufacturer remains responsible for Part 211 compliance, but it relies on suppliers whose materials and quality systems meet the relevant standards. A packaging supplier therefore supports Part 211 indirectly: by certifying to ISO 15378, supplying components that meet the applicable USP requirements, and providing the documentation its customers need.

How this works in practice at Autofits

Autofits is a manufacturer of primary packaging (aluminium and aluminium-plastic vial seals and caps), not a finished-drug manufacturer, so 21 CFR Part 211 applies to its pharmaceutical customers rather than to Autofits directly. Autofits supports those customers’ cGMP obligations by operating an ISO 15378:2017 quality system, the GMP-aligned standard for primary packaging materials, alongside ISO 9001:2015 and ISO 14001:2015 certification and a Drug Master File. The FlipTop Optima flip-off seals, tear-off and tear-down aluminium seals, and aluminium pilfer-proof (ROPP) caps (the full products page lists the range) are produced in a 75,000 sq ft Nashik facility with an ISO Class 8 cleanroom and high-speed visual inspection, with the documentation and consistency that customers’ container-closure control requires. The full certification set is on the quality page.

Frequently asked questions

What is 21 CFR Part 211?

21 CFR Part 211 is the U.S. FDA regulation setting the current good manufacturing practice (cGMP) requirements for finished pharmaceuticals. It covers organisation, facilities, equipment, components and containers, production, packaging and labeling, holding and distribution, laboratory controls, and records. A product not made in compliance with cGMP is considered adulterated under U.S. law.

What does Part 211 say about packaging?

Part 211 requires that drug product containers and closures be suitable and not be reactive, additive, or absorptive to an extent that alters the drug beyond established requirements. Subpart E governs the control of components and container-closure systems, and Subpart G governs the packaging and labeling operation, including controls to prevent mix-ups and tamper-evident features where required.

Does 21 CFR Part 211 apply to packaging suppliers?

Part 211 applies directly to manufacturers of finished pharmaceuticals, not to packaging-component suppliers. A packaging supplier supports its customers’ Part 211 compliance indirectly, typically by operating a quality system certified to ISO 15378, supplying components that meet the applicable USP requirements, and providing documentation. The drug manufacturer remains responsible for its own cGMP compliance.

What is the difference between 21 CFR Part 210 and Part 211?

Part 210 sets out the general scope and applicability of cGMP for drugs, while Part 211 contains the detailed cGMP requirements for finished pharmaceuticals. In practice, Part 211 is the operative regulation with the specific requirements for manufacturing, packaging, and controls.

How does Part 211 relate to ISO 15378?

Part 211 is a binding U.S. regulation for finished-drug makers; ISO 15378 applies GMP principles to the manufacturers of primary packaging materials. A packaging supplier certified to ISO 15378 produces components under a GMP-aligned quality system, which supports its pharmaceutical customers in meeting the container-closure and component-control expectations of Part 211.

Related reading

Sources

  • U.S. FDA / eCFR: Title 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211)
  • U.S. FDA: Facts About the Current Good Manufacturing Practices (CGMP) (https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations)
  • ISO: ISO 15378:2017, Primary packaging materials for medicinal products (https://www.iso.org/standard/70845.html)

*Last updated: 2026-06-18. This article is general regulatory information, not legal or compliance advice; confirm current regulatory text and requirements with the FDA and the eCFR.*

Back to top: